Abbott excels on power of brands, outpaces MNC peers on sales growth

Abbott India, the listed subsidiary of the US-based pharma giant, has outpaced its multinational peers to register a 14.6 per cent growth in sales to Rs 25.19 billion in nine months of the current financial.

The growth has come at a time when GST implementation affected most Indian pharma companies including Abbott’s MNC peers. Some of their products have also been impacted by growing list of NLEM (National List of Essential Medicines) products.

This saw UK based GlaxoSmithKline and the US-based Pfizer report negative sales growth of respectively 2 per cent and 5.2 per